Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) EBITDA Margin (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EBITDA Margin for 15 consecutive years, with 320.83% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 6756.0% to 320.83% in Q3 2025 year-over-year; TTM through Sep 2025 was 255.91%, a 192.0% decrease, with the full-year FY2024 number at 252.32%, up 1882.0% from a year prior.
  • EBITDA Margin was 320.83% for Q3 2025 at Plus Therapeutics, down from 110.65% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1749.5% in Q3 2021 to a low of 6978.08% in Q3 2022.
  • A 5-year average of 782.23% and a median of 276.2% in 2024 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -872758bps in 2022, then skyrocketed 670717bps in 2023.
  • Plus Therapeutics' EBITDA Margin stood at 1749.5% in 2021, then plummeted by -351bps to 4387.4% in 2022, then soared by 93bps to 293.83% in 2023, then rose by 6bps to 276.2% in 2024, then dropped by -16bps to 320.83% in 2025.
  • Per Business Quant, the three most recent readings for PSTV's EBITDA Margin are 320.83% (Q3 2025), 110.65% (Q2 2025), and 333.9% (Q1 2025).